Prime Medicine, Inc. Common Stock (PRME) support and resistance · rev $3.0M
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
This page maps Prime Medicine, Inc. Common Stock (PRME) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported PRME revenue for 2024-12-31 was $3.0M. Net income was -$195.9M. PRME currently screens at market cap $570.8M.
PRME currently screens at market cap $570.8M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new PRME 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the PRME quote page for the session range and the stock page for the full model.
Not investment advice.